… already existing radioconjugate pipeline of AstraZeneca, such as Enhertu, which has … weighting nature of healthcare, with AstraZeneca being a leading constituent. The … only strengthens the pipeline of AstraZeneca but also highlights the significance …

AstraZeneca announced on Wednesday that the …

… . Tezspire is being developed by AstraZeneca in collaboration with Amgen Inc … Oaks, California-based biotechnology company. Astrazeneca said regulatory applications are currently … the BioPharmaceuticals Business Unit at AstraZeneca, said: "In Europe, we …

My professional life didn’t follow a linear trajectory, right? This is based on my personality, which is exciting. I like curiosity, to try new things and take calculated risks. I’m from Kosovo originally. When I returned to Kosovo and after we got …

… muscle-invasive bladder cancer. AstraZeneca has shared new data … oncology hematology R&D, AstraZeneca, added: “The early and … Phase III trial. News release. AstraZeneca. October 17, 2025. Accessed … https://www.astrazeneca-us.com/content…

AstraZeneca announced October 15 that it … the blood. In a statement, AstraZeneca’s Senior VP in charge …

AstraZeneca Plc and Daiichi Sankyo Co. … has risen 33% this year. AstraZeneca climbed as much as 1% …

… the disease. According to AstraZeneca, the antibody-drug conjugate … Mohit Manrao, head of AstraZeneca’s U.S. oncology … or death, AstraZeneca said. According to Manrao, AstraZeneca generally expected to … related to the drug. AstraZeneca said this event was …

… Glenn Youngkin announced that AstraZeneca will officially invest $4 … President Donald Trump highlighted AstraZeneca’s broader $50 billion … and data analytics. AstraZeneca said the facility will … year. Pascal Soriot, AstraZeneca’s chief executive officer, …